-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PH-762 in Head And Neck Squamous Cell Carcinoma (HNSC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PH-762 in Head And Neck Squamous Cell Carcinoma (HNSC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PH-762 in Head And Neck Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PH-762 in Merkel Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PH-762 in Merkel Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PH-762 in Merkel Cell Carcinoma Drug Details: PH-762 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PH-762 in Cutaneous Squamous Cell Carcinoma (cSCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PH-762 in Cutaneous Squamous Cell Carcinoma (cSCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PH-762 in Cutaneous Squamous Cell Carcinoma (cSCC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PH-762 in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PH-762 in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PH-762 in Solid Tumor Drug Details: PH-762 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PH-762 in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PH-762 in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PH-762 in Metastatic Melanoma Drug Details: PH-762 is under development for...
-
Innovation Ranking
Innovation Ranking – Phio Pharmaceuticals Corp
Phio Pharmaceuticals Corp (Phio Pharmaceuticals), formerly known as RXi Pharmaceuticals Corp, is a biotechnology company. The company discovers, develops and commercializes immuno-oncology therapeutics based RNAi platform to treat cancer. Its product pipeline includes PH-762, PH-894 and PH-804 for adoptive cell therapy, tumor microenvironment and intratumoral. Phio Pharmaceuticals also provides clinical trial services. Phio Pharmaceuticals offers products for the treatment of anti scarring, macular degeneration, retinoblastoma, and liver diseases. The company partners with academia, biotech, and large multi-national organizations for the...
-
Product Insights
NewMerkel Cell Carcinoma – Drugs In Development, 2024
Empower your strategies with our Merkel Cell Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, ultraviolet exposure, and immune suppression. Symptoms include painless nodules on the skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and...
-
Product Insights
NewColon Carcinoma – Drugs In Development, 2024
Empower your strategies with our Colon Carcinoma – Drugs In Development, 2024 report and make more profitable business decisions. Colon carcinoma is a type of cancer that affects the large intestine, which includes the colon and the rectum. It is one of the most common cancers worldwide and can cause symptoms such as blood in the stool, weight loss, and fatigue. Colon carcinoma usually develops from benign growths called polyps that form on the inner lining of the colon or rectum....
-
Product Insights
NewAlopecia Areata – Drugs In Development, 2024
Empower your strategies with our Alopecia Areata – Drugs In Development, 2024 report and make more profitable business decisions. Alopecia areata is an autoimmune condition characterized by unpredictable, patchy hair loss. It occurs when the immune system mistakenly attacks hair follicles, leading to hair loss in small, round patches on the scalp or other parts of the body. In some cases, it can progress to total hair loss (alopecia totalis) or loss of hair on the entire body (alopecia universalis). The...
-
Product Insights
NewAlopecia – Drugs In Development, 2024
Empower your strategies with our Alopecia – Drugs In Development, 2024 report and make more profitable business decisions. Alopecia is the partial or complete loss of hair, especially on the scalp; it can occur in patches, on the entire head, or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, exposure to irritants or toxins, burns, injuries, and infections. The Alopecia drugs in development market research report provide comprehensive information on the therapeutics under...